Table III.
Associations of itch with symptoms of anxiety and depression and sleep disturbance by skin diseases
| Group | Associations of itch NRS score with scores of other PROs (adjusted β, 95% UI)∗ |
||
|---|---|---|---|
| PHQ-2 | GAD-2 | PSQI | |
| Healthy controls | 0.18 (0.16, 0.19) | 0.18 (0.17, 0.19) | 0.50 (0.47, 0.53) |
| Noncommunicable skin diseases† | 0.15 (0.13, 0.17) | 0.15 (0.14, 0.17) | 0.38 (0.34, 0.42) |
| Moderate-to-severe acne | 0.15 (0.13, 0.18) | 0.17 (0.14, 0.19) | 0.43 (0.37, 0.49) |
| Eczema | 0.13 (0.10, 0.17) | 0.14 (0.11, 0.17) | 0.34 (0.28, 0.39) |
| Atopic dermatitis | 0.13 (0.10, 0.17) | 0.13 (0.09, 0.16) | 0.34 (0.26, 0.41) |
| Chronic urticaria | 0.14 (0.10, 0.18) | 0.12 (0.08, 0.17) | 0.36 (0.26, 0.46) |
| Chronic spontaneous urticaria | 0.18 (0.13, 0.24) | 0.14 (0.09, 0.20) | 0.38 (0.25, 0.52) |
| Chronic inducible urticaria | 0.06 (0.00, 0.13) | 0.09 (0.03, 0.16) | 0.31 (0.17, 46) |
| Psoriasis | 0.07 (–0.05, 0.20) | 0.18 (0.01, 0.35) | 0.41 (0.14, 0.70) |
| Vitiligo | 0.10 (–0.06, 0.27) | 0.03 (–0.13, 0.18) | 0.18 (–0.22, 0.57) |
| Rosacea | 0.22 (0.17, 0.27) | 0.21 (0.16, 0.26) | 0.36 (0.27, 0.46) |
GAD-2, Generalized Anxiety Disorder–2; NRS, numeric rating scale; PHQ, 2-item Patient Health Questionnaire; PRO, patient-reported outcome; PSQI, Pittsburgh Sleep Quality Index; UI, uncertainty interval.
∗
Adjusted for level 1 covariates (age and sex) and level 2 random effects (university).
†
This is a combined group of all the conditions listed beneath it (as subsets).